Sign in
Taking people in FrancePhase 1/2

SENS-601 injected into the inner ear for children with GJB2-related hearing loss

Tests SENS-601 injected into the cochlea in children with GJB2-related hearing loss.

Key facts

Who runs it
Sensorion
Where
Paris, FranceSee the site
Registry title
A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 Gene
Status
Recruiting
Phase
Phase 1/2
People taking part
18 people, planned
Starts
Jan 2027
Expected to end
Dec 2034
Type of study
Interventional, 3 groups
Treatments tested
  • SENS-601 administration
Record updated
17 November 2026

Who can take part

Age
6 months to 6 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (9)Hide the full registry criteria

Who can take part

  • Males or females aged ≥6 months to ≤6 years
  • Congenital bilateral severe sensorineural hearing loss
  • Biallelic GJB2 variation(s)
  • Documented normal cochlea and internal auditory canals

Who cannot take part

  • Have been dosed in a previous gene therapy clinical study
  • Prior or current cochlear implant in the ear to be treated with SENS-601
  • Contraindication to corticosteroid therapy and/or immunosuppressive or immunomodulatory therapy or to the planned surgery, to anesthesia or increased anesthesiologic risk
  • History of chronic, acute, or major disease
  • Other causes or risk of hearing loss, including developmental disorders, unilateral hearing loss, chronic conductive hearing loss, malformation syndrome, syndromic hearing loss or any other cause that would impact negatively the response of hair cell function, history of therapy known as ototoxic for an extended period, or documented other causes of congenital bilateral hearing loss linked to mutations in genes other than GJB2

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in France.

  • Hopital Necker Enfants MaladesParis, FranceTaking people

About the trial

What the trial wants to find out

This study intends to assess safety, tolerability, and efficacy of SENS-601, injected with SPHYNX administration system, in children between 6 months and 6 years of age, with hearing loss related to pathogenic variation(s) of GJB2 gene.

The 3 groups in the trial

  • Dose escalation - Dose Level 1Treatment being tested

    Intracochlear administration of Dose level 1 of SENS-601 in one ear, with the SPHYNX injection system

    Treatment: SENS-601 administration

  • Dose escalation - Dose Level 2Treatment being tested

    Intracochlear administration of Dose level 2 of SENS-601 in one ear, with the SPHYNX injection system

    Treatment: SENS-601 administration

  • Dose expansion groupTreatment being tested

    Intracochlear administration of SENS-601 in both ears, with the SPHYNX injection system, at the dose recommended following the Dose escalation phase

    Treatment: SENS-601 administration

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, A4, 1 to 2 pages. US Letter size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-Label, Multicenter Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of Intracochlear Ascending Dose Injections of SENS-601 Followed by Expansion Cohort in Pediatric Population With Hearing Loss Related to Biallelic Pathogenic Variation(s) of GJB2, As Well As to Demonstrate the Performance of the Administration System, Its Safety, Its Clinical Benefit, and Its Usability
Plain-language title
SENS-601 injected into the inner ear for children with GJB2-related hearing lossGenerated from the registry record. The registry title is the official one.
Criteria questions
Built from NCT07941115, who can take part
Record updated
17 November 2026